NewsEvents

Your Yourlocation: Home > Clinical value of tiotropium bromide(136310-93-5) in the treatment of pneumoconiosis with chronic obstructive pulmonary disease

To investigate the clinical value of tiotropium bromide(136310-93-5) in the treatment of pneumoconiosis with chronic obstructive pulmonary disease. Methods: 110 patients with pneumoconiosis and chronic obstructive pulmonary disease treated in Shenyang from April 2015 to April 2016 were selected as the study. The patients were divided into observation group and control group according to the random number table method, 55 cases were treated in the control group. The patients in the observation group were treated with tiotropium bromide on the basis of this, and the clinical data of the two groups were compared (P <0.05). After treatment, the vital capacity (FCV) of the patients in the observation group was significantly higher than that in the control group (P <0.05) .There was significant difference between the two groups (P> 0.05) (FEV1), FE flight rate (PEF) and FEV1 /FCV were significantly higher than those in the control group, the difference was statistically significant (both P <0.05) .Conclusion: The clinical effect of tiotropium bromide(136310-93-5) in the treatment of pneumoconiosis with chronic obstructive pulmonary disease is significant, which can improve the lung function and safety of patients with chronic obstructive pulmonary disease.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved